This study examines acute pharyngitis, which is an inflammation of the throat that causes soreness and discomfort. The study will test lozenges containing two active substances: benzydamine hydrochloride and 2,4 dichlorobenzyl alcohol. These substances work together to reduce inflammation and provide local numbing effects in the throat. The study will compare these lozenges with another product already available on the market and with placebo. The purpose of this study is to determine how well the lozenges work in relieving symptoms of acute pharyngitis and to assess their safety.

Participants in this study will be adults who have recently developed acute pharyngitis with significant throat soreness that started within the last 30 hours. The study is designed so that neither the participants nor the researchers know which treatment is being given during the trial. Each person will receive lozenges to dissolve slowly in the mouth. The treatment will last for up to 4 days, during which participants will need to use an electronic device such as a smartphone or tablet to record information about their symptoms.

The main focus of the study is to measure how much the throat soreness improves during the first 2 hours after taking the first lozenge. Researchers will track changes in throat pain intensity by comparing the new lozenges with both placebo and the existing market product. All three types of lozenges are taken in the same way, by placing them in the mouth and allowing them to dissolve slowly. The maximum daily dose is 25.2 milligrams, and the total amount used over the treatment period will not exceed 84 milligrams.